Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lipocine (LPCN) Return on Sales (2018 - 2025)

Historic Return on Sales for Lipocine (LPCN) over the last 8 years, with Q3 2025 value amounting to 27.81%.

  • Lipocine's Return on Sales fell 272700.0% to 27.81% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.27%, marking a year-over-year decrease of 7300.0%. This contributed to the annual value of 0.0% for FY2024, which is 57400.0% up from last year.
  • According to the latest figures from Q3 2025, Lipocine's Return on Sales is 27.81%, which was down 272700.0% from 3.54% recorded in Q2 2025.
  • In the past 5 years, Lipocine's Return on Sales ranged from a high of 275.49% in Q2 2021 and a low of 219.28% during Q2 2023
  • Over the past 5 years, Lipocine's median Return on Sales value was 2.13% (recorded in 2023), while the average stood at 6.51%.
  • Per our database at Business Quant, Lipocine's Return on Sales skyrocketed by 2029900bps in 2021 and then plummeted by -2807600bps in 2022.
  • Quarter analysis of 5 years shows Lipocine's Return on Sales stood at 0.78% in 2021, then crashed by -2842bps to 21.52% in 2022, then skyrocketed by 149bps to 10.56% in 2023, then crashed by -95bps to 0.51% in 2024, then plummeted by -5549bps to 27.81% in 2025.
  • Its Return on Sales was 27.81% in Q3 2025, compared to 3.54% in Q2 2025 and 19.87% in Q1 2025.